Tajikistan has received another consignment of Moderna COVID-19 vaccine through the COVID-19 Vaccines Global Access (COVAX) facility.
650,400 doses of Moderna vaccine have arrived in Tajikistan through COVAX facility as part of the World Bank's grant project, the Ministry of Health and Social Protection of the Population (MoHSPP) said Friday (January 21) morning.
Moderna’s COVID-19 vaccine received a WHO Emergency Use Listing (EUL) on April 30, 2021. On May 3, 2021, the COVAX Facility announced that it had signed an Advance Purchase Agreement to secure access to 34 million doses of COVID-19 vaccines from Moderna in the fourth quarter of 2021 and up to 466 million doses in 2022.
In Tajikistan, COVID-19 vaccination is compulsory for people aged 18 and over. Five types of the COVID-19 vaccine are currently used for vaccination of the population in Tajikistan: CoronaVac; AstraZeneca; Moderna; Pfizer; and Sputnik V.
Vaccination against COVID-19 is mandatory in Tajikistan for citizens above 18 years since July 3, 2021.
As of January 20, some 4,312,774 were reportedly vaccinated against COVID-19 in Tajikistan. The country targets to vaccinate 5,826,301.
As of January 20, 2022, 4,312,774 residents of Tajikistan have reportedly been vaccinated against the novel coronavirus (COVID-19. At least 79 percent of the country’s adult population has received at least one dose of the COVID-19 vaccine as of January 20, and at least 63 percent of Tajikistan’s adult population has got both COVID-19 vaccine shots as of January 20.
According to the latest statistics and official information about the coronavirus situation posted on the MoHSPP’s website on December 6, 2021, there have been 17,095 infections and 124 coronavirus-related deaths reported in Tajikistan since the pandemic began. 16,966 COVID-19 patients have reportedly recovered.
